Weekly briefing
The week in TV and media buying
Week 34 · August 17, 2026 — August 23, 2026
The through-line this week is measurement credibility: Nielsen's own neuroscience team is flagging holes in how meters register attention just as BrightEdge shows AI answer engines are already rewriting where purchase credit lands. Snap's pharma format is a smaller, operational item for anyone running health accounts, unrelated to the measurement story.
Nielsen neuro study finds second screens cause 25% of panelists to miss meter prompts
mediapost.com ↗What changed in the work
Nielsen's own research team is now surfacing evidence, from a small lab study, that meter-based panels can miss real viewing behavior when a second screen is in play, which is a crack in the currency data your plans are built on rather than a ratings change.
On Monday
Pull the co-viewing assumptions baked into your national TV plan's daypart weighting and check whether they treat all co-viewing dayparts as equally attentive — CRE's data shows the attention lift from co-viewing (15%→20%) disappears once a second screen is present. Ask your measurement partner whether their panel adjusts for that or is still applying a flat co-viewing multiplier, and hold off on re-underwriting reach until CRE's in-home follow-up lands.
BrightEdge: Google AI Overviews leans local, ChatGPT leans on deals and pricing
mediapost.com ↗What changed in the work
Google AI Overviews and ChatGPT are pulling different signals when they cite a brand in a transactional answer, so the content that earns you visibility in one engine is close to irrelevant in the other.
On Monday
Check that your client's product pages lead with current pricing and deal terms — that's the content driving 44% of ChatGPT's transactional citations — and verify retailer-partner listings (Amazon, big-box) are accurate, since Google AI Overviews names the retailer over the brand itself 85% of the time in lower-funnel answers. Also shift your Instagram content plan toward price/availability posts and route returns or troubleshooting content to Facebook, matching where BrightEdge found each platform actually gets cited.
Snap launches multi-CTA ad format for compliant pharma campaigns
mediapost.com ↗What changed in the work
Snap now lets pharma advertisers attach compliant disclaimer and safety-info links directly inside the ad unit, removing the format gap that's kept Rx spend off the platform.
On Monday
If you handle a pharma or OTC account, ask your Snap rep for the multi-CTA spec sheet and set up a small test line in Snap Ads or Story Ads to see how disclaimer tap-through performs against your current compliant-format channels. Don't route budget into Sponsored Snaps for this yet, since that placement isn't live until end of 2026.